Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Albaconazole · 2 trials · 1 indication
At each study visit, the investigator assessed the percentage of affected toenail on the target nail by estimating the percent affected nail in each quadrant, summing the percent affected in each quadrant and dividing the sum by 4. Effective treatment was defined as a mycological cure and clear or almost clear nail (distal subungual hyperkeratosis and/or onycholysis leaving less than 10% of nail plate effected). Comparisons were carried out in a sequential step-down fashion, combined with the Holm procedure at step 2. P-value was based on a sequential step-down combined with the Holm procedure. It was assessed on Week 4, 8, 12, 16, 20, 24, 30, 36, 44 and 52.
| Arm | Type | Description |
|---|---|---|
| Albaconazole 100mg | ACTIVE_COMPARATOR | Albaconazole for 36 weeks |
| Albaconazole 200mg | ACTIVE_COMPARATOR | Albaconazole for 36 weeks |
| Albaconazole 400mg | ACTIVE_COMPARATOR | Albaconazole for 36 weeks |
| Albaconazole 400mg 24 weeks, Placebo 12 weeks | ACTIVE_COMPARATOR | Albaconazole for 24 weeks, Placebo for 12 weeks |
| Placebo 400 mg | PLACEBO_COMPARATOR | Placebo for 36 weeks |
| 1 | EXPERIMENTAL | Subjects randomized to study product sequence 1 will receive the single albaconazole 400-mg tablet during the first dosing period and the four 100-mg albaconazole capsules during the second dosing period. |
| 2 | EXPERIMENTAL | Subjects randomized to study product sequence 2 will receive the four 100-mg albaconazole capsules during the first dosing period and the single albaconazole 400-mg tablet during the second dosing period. |
| Name | Type | Description |
|---|---|---|
| Albaconazole 100mg | DRUG | Albaconazole for 36 weeks |
| Albaconazole 200mg | DRUG | Albaconazole for 36 weeks |
| Albaconazole 400mg | DRUG | Albaconazole for 36 weeks |
| Placebo 400 mg | DRUG | Placebo for 36 weeks |
| Albaconazole tablet 400mg | DRUG | Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose |
| Albaconazole 100mg capsules, then albaconazole 400mg tablet | DRUG | Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose |
Inclusion Criteria: * Subject aged 18 to 75 years. * Diagnosis with distal subungual onychomycosis of the toenails that affects at least one great toe (target toenail). * Subject is willing to provide signed and dated written voluntary informed consent (and any local or national authorization requi...
Albaconazole is an investigational small molecule being developed for onychomycosis, a fungal infection of the nail. It is in Phase 2 clinical development and has been studied in patients with distal subungual onychomycosis. The drug is not approved and remains under clinical investigation.
Albaconazole is being developed by GSK plc, which trades under the ticker GSK. The company has sponsored clinical trials of the drug for onychomycosis. GSK is the developer of record for the investigational agent.
Albaconazole is in Phase 2 clinical development for onychomycosis. It has completed two clinical trials, including a Phase 2 efficacy and safety study and a Phase 1 pharmacokinetic study. The drug is investigational and has not been approved by regulatory authorities.
Albaconazole has been studied in two completed trials. NCT00730405 was a Phase 2 study of four dose regimens in 582 subjects with distal subungual onychomycosis. NCT01039883 was a Phase 1 study comparing blood levels of a 400 mg tablet versus capsule in 40 healthy subjects.
Albaconazole is a distinct investigational compound and is not known by any alternative names. It is being studied specifically for onychomycosis and has no other reported designations in clinical development.